Dr. Karen Reckamp, MD
Claim this profileTorrance Memorial Physician Network - Cancer Care
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
7 reported clinical trials
11 drugs studied
Area of expertise
1Lung Cancer
Stage IV
MET positive
NRG1 positive
2Non-Small Cell Lung Cancer
Stage IV
MET positive
PD-L1 positive
Affiliated Hospitals
Clinical Trials Karen Reckamp, MD is currently running
Ramucirumab + Pembrolizumab vs Chemotherapy
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Recruiting2 awards Phase 310 criteria
Tepotinib + Ramucirumab
for Lung Cancer
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.
Recruiting1 award Phase 24 criteria
More about Karen Reckamp, MD
Clinical Trial Related4 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Karen Reckamp, MD has experience with
- Pembrolizumab
- Ramucirumab
- Seribantumab
- Talazoparib
- Atezolizumab
- Screening Platform
Breakdown of trials Karen Reckamp, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Head and Neck Cancers
Ovarian Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Karen Reckamp, MD specialize in?
Karen Reckamp, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are MET positive.
Is Karen Reckamp, MD currently recruiting for clinical trials?
Yes, Karen Reckamp, MD is currently recruiting for 4 clinical trials in Torrance California. If you're interested in participating, you should apply.
Are there any treatments that Karen Reckamp, MD has studied deeply?
Yes, Karen Reckamp, MD has studied treatments such as Pembrolizumab, Ramucirumab, Seribantumab.
What is the best way to schedule an appointment with Karen Reckamp, MD?
Apply for one of the trials that Karen Reckamp, MD is conducting.
What is the office address of Karen Reckamp, MD?
The office of Karen Reckamp, MD is located at: Torrance Memorial Physician Network - Cancer Care, Torrance, California 90505 United States. This is the address for their practice at the Torrance Memorial Physician Network - Cancer Care.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.